Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours

A Taiwanese Gynecologic Oncology Group study

Chi An Chen, Hao Lin, Chia Sui Weng, Kuo Chang Wen, Chien Hsing Lu, Hung Hsueh Chou, Yu-Fang Huang, Chieh Yi Kang, Chih Ming Ho, Mu Hsien Yu, Cheng-Yang Chou

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background The combination of bleomycin, etoposide and cisplatin (BEP) is currently the most widely used treatment for malignant ovarian germ cell tumours (MOGCTs). The aim of this study was to evaluate the efficacy and adverse effects of the 3-day BEP regimen in Taiwan. The prognostic factors of the MOGCT patients were also analysed. Patients and methods Two hundred and thirty-nine cases of MOGCTs were identified from the Taiwanese Gynecologic Oncology Group database, and 204 of those who received postoperative BEP chemotherapy were then analysed. Results The estimated rate of no evidence of disease was 94.0% for 204 patients with adjuvant BEP regimen. Seven grade 3/4 haematological adverse effects including four subjects with neutropenia, one with pancytopenia and two with neutropenic fever were recorded in the 853 total courses of chemotherapeutic cycles. The rates of haematological and non-haematological adverse effects were 0.82% and 2.3%, respectively. No treatment-related mortality was noted. In the analysis of prognostic factors, only tumour stage had a significant impact on disease recurrence (95% confidence interval (CI), 4.2-94.4, p < 0.001) and disease-related mortality (95% CI, 2.2-163.9, p = 0.007). Conclusions The current 3-day adjuvant BEP regimen was effective and safe for patients with MOGCTs.

Original languageEnglish
Pages (from-to)3161-3167
Number of pages7
JournalEuropean Journal of Cancer
Volume50
Issue number18
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Germ Cell and Embryonal Neoplasms
Bleomycin
Etoposide
Cisplatin
Confidence Intervals
Pancytopenia
Mortality
Neutropenia
Taiwan
Fever
Databases
Recurrence
Drug Therapy
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Chen, Chi An ; Lin, Hao ; Weng, Chia Sui ; Wen, Kuo Chang ; Lu, Chien Hsing ; Chou, Hung Hsueh ; Huang, Yu-Fang ; Kang, Chieh Yi ; Ho, Chih Ming ; Yu, Mu Hsien ; Chou, Cheng-Yang. / Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours : A Taiwanese Gynecologic Oncology Group study. In: European Journal of Cancer. 2014 ; Vol. 50, No. 18. pp. 3161-3167.
@article{06533a95311e4a218f5ededd4f995362,
title = "Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: A Taiwanese Gynecologic Oncology Group study",
abstract = "Background The combination of bleomycin, etoposide and cisplatin (BEP) is currently the most widely used treatment for malignant ovarian germ cell tumours (MOGCTs). The aim of this study was to evaluate the efficacy and adverse effects of the 3-day BEP regimen in Taiwan. The prognostic factors of the MOGCT patients were also analysed. Patients and methods Two hundred and thirty-nine cases of MOGCTs were identified from the Taiwanese Gynecologic Oncology Group database, and 204 of those who received postoperative BEP chemotherapy were then analysed. Results The estimated rate of no evidence of disease was 94.0{\%} for 204 patients with adjuvant BEP regimen. Seven grade 3/4 haematological adverse effects including four subjects with neutropenia, one with pancytopenia and two with neutropenic fever were recorded in the 853 total courses of chemotherapeutic cycles. The rates of haematological and non-haematological adverse effects were 0.82{\%} and 2.3{\%}, respectively. No treatment-related mortality was noted. In the analysis of prognostic factors, only tumour stage had a significant impact on disease recurrence (95{\%} confidence interval (CI), 4.2-94.4, p < 0.001) and disease-related mortality (95{\%} CI, 2.2-163.9, p = 0.007). Conclusions The current 3-day adjuvant BEP regimen was effective and safe for patients with MOGCTs.",
author = "Chen, {Chi An} and Hao Lin and Weng, {Chia Sui} and Wen, {Kuo Chang} and Lu, {Chien Hsing} and Chou, {Hung Hsueh} and Yu-Fang Huang and Kang, {Chieh Yi} and Ho, {Chih Ming} and Yu, {Mu Hsien} and Cheng-Yang Chou",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ejca.2014.10.006",
language = "English",
volume = "50",
pages = "3161--3167",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "18",

}

Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours : A Taiwanese Gynecologic Oncology Group study. / Chen, Chi An; Lin, Hao; Weng, Chia Sui; Wen, Kuo Chang; Lu, Chien Hsing; Chou, Hung Hsueh; Huang, Yu-Fang; Kang, Chieh Yi; Ho, Chih Ming; Yu, Mu Hsien; Chou, Cheng-Yang.

In: European Journal of Cancer, Vol. 50, No. 18, 01.01.2014, p. 3161-3167.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours

T2 - A Taiwanese Gynecologic Oncology Group study

AU - Chen, Chi An

AU - Lin, Hao

AU - Weng, Chia Sui

AU - Wen, Kuo Chang

AU - Lu, Chien Hsing

AU - Chou, Hung Hsueh

AU - Huang, Yu-Fang

AU - Kang, Chieh Yi

AU - Ho, Chih Ming

AU - Yu, Mu Hsien

AU - Chou, Cheng-Yang

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background The combination of bleomycin, etoposide and cisplatin (BEP) is currently the most widely used treatment for malignant ovarian germ cell tumours (MOGCTs). The aim of this study was to evaluate the efficacy and adverse effects of the 3-day BEP regimen in Taiwan. The prognostic factors of the MOGCT patients were also analysed. Patients and methods Two hundred and thirty-nine cases of MOGCTs were identified from the Taiwanese Gynecologic Oncology Group database, and 204 of those who received postoperative BEP chemotherapy were then analysed. Results The estimated rate of no evidence of disease was 94.0% for 204 patients with adjuvant BEP regimen. Seven grade 3/4 haematological adverse effects including four subjects with neutropenia, one with pancytopenia and two with neutropenic fever were recorded in the 853 total courses of chemotherapeutic cycles. The rates of haematological and non-haematological adverse effects were 0.82% and 2.3%, respectively. No treatment-related mortality was noted. In the analysis of prognostic factors, only tumour stage had a significant impact on disease recurrence (95% confidence interval (CI), 4.2-94.4, p < 0.001) and disease-related mortality (95% CI, 2.2-163.9, p = 0.007). Conclusions The current 3-day adjuvant BEP regimen was effective and safe for patients with MOGCTs.

AB - Background The combination of bleomycin, etoposide and cisplatin (BEP) is currently the most widely used treatment for malignant ovarian germ cell tumours (MOGCTs). The aim of this study was to evaluate the efficacy and adverse effects of the 3-day BEP regimen in Taiwan. The prognostic factors of the MOGCT patients were also analysed. Patients and methods Two hundred and thirty-nine cases of MOGCTs were identified from the Taiwanese Gynecologic Oncology Group database, and 204 of those who received postoperative BEP chemotherapy were then analysed. Results The estimated rate of no evidence of disease was 94.0% for 204 patients with adjuvant BEP regimen. Seven grade 3/4 haematological adverse effects including four subjects with neutropenia, one with pancytopenia and two with neutropenic fever were recorded in the 853 total courses of chemotherapeutic cycles. The rates of haematological and non-haematological adverse effects were 0.82% and 2.3%, respectively. No treatment-related mortality was noted. In the analysis of prognostic factors, only tumour stage had a significant impact on disease recurrence (95% confidence interval (CI), 4.2-94.4, p < 0.001) and disease-related mortality (95% CI, 2.2-163.9, p = 0.007). Conclusions The current 3-day adjuvant BEP regimen was effective and safe for patients with MOGCTs.

UR - http://www.scopus.com/inward/record.url?scp=84925227182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925227182&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2014.10.006

DO - 10.1016/j.ejca.2014.10.006

M3 - Article

VL - 50

SP - 3161

EP - 3167

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 18

ER -